(lp0
S'Maxim Analyst Comments on Cytori Therapeutics Inc Following Azaya Acquisition Smarter Analyst - Jan 19, 2017 Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc  with a price target of $6.00, after the drug developer announced the acquisitions of Azaya Therapeutics for its proprietary liposomal nanoparticle&nbsp;...Cytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya ... - MarketWatchCytori Therapeutics  to Acquire Assets from Privately Held Azaya ... - StreetInsider.com'
p1
aS"Maxim's Biotech Insights: Cytori Therapeutics Inc , StemCells Inc  Smarter Analyst - Mar 28, 2016 Recent developments in biotech stocks Cytori Therapeutics Inc  and StemCells Inc  attract analysts' attention as pipeline treatments inch toward the end of their final testing phases."
p2
aS"Important Detailed Discussion about Cytori Therapeutics, Inc.'s  stock ... Hot Stocks Point - 4 hours ago USA based company, Cytori Therapeutics, Inc. 's latest closing price distance was at -11.25% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -0.06% and -1.37% compared with the 20 Day Moving&nbsp;..."
p3
aS'Stock Update : Cytori Therapeutics Inc Announces Increase of ... Smarter Analyst - Sep 19, 2016 Cytori Therapeutics Inc  announced that the Company and Biomedical Advanced Research and Development Authority , a division of the U.S.'
p4
aS'Correcting The Facts On Cytori Therapeutics Seeking Alpha - Apr 14, 2015 On April 8th, 2015, TheStreet.com published an article by Adam Feuerstein on Cytori Therapeutics . The article was notable for its vindictiveness as it skewered the company for a Benzinga article that included an interview with Cytori CEO,&nbsp;...'
p5
aS'Stock Update : Cytori Therapeutics Inc Partner Kerastem Completes ... Smarter Analyst - Sep 26, 2016 Cytori Therapeutics Inc  announced that its licensee Kerastem Technologies, LLC, has completed enrollment of STYLE, a US phase II clinical trial investigating early stage female and male pattern hair loss.'
p6
aS'Cytori Therapeutics, Inc.  PT Raised to $10 at Maxim Group on Closure of ... StreetInsider.com - Feb 15, 2017 Maxim Group raised its price target on Cytori Therapeutics, Inc.  to $10.00  while maintaining a Buy rating.Cytori Therapeutics Inc.: Cytori Completes Acquisition of Azaya Therapeutics ... - The Wall Street Transcript'
p7
aS"Cytori Therapeutics'  CEO Marc Hedrick on Q1 2016 Results - Earnings ... Seeking Alpha - May 11, 2016 Second, management feels that the combination of the forecasted spend and revenue may be sufficient to get the Company to the point of breakeven by 2018.Stock Update : Cytori Therapeutics Inc Granted Broad European ... - Smarter Analyst"
p8
aS'Cytori Therapeutics Inc  Stock Rating Upgraded by Zacks Investment Research Chaffey Breeze - Mar 14, 2017 Cytori Therapeutics logo Cytori Therapeutics Inc  was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued to clients and investors on Monday.Cytori Therapeutics Inc  has been upgraded to Hold in a statement ... - Breaking Finance NewsCytori Therapeutics Inc - Receive News &amp; Ratings Daily - BBNS'
p9
aS'Cytori to Webcast Fourth Quarter Financial Results on March 23rd GlobeNewswire  - Mar 17, 2017 Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions.Should Farsighted Investors Pay Attention to Cytori Therapeutics, Inc. (NASDAQ ... - Morgan Research'
p10
a.